This application requests renewal for years 29-33 of the NCI Cancer Center Support Grant (CCSG) for the Barbara Ann Karmanos Cancer Institute (KCI) at Wayne State University. The Programs of KCI reflect the cancer needs of the greater Metropolitan Detroit area. This is an industrialized, urban and ethnically diverse community with a disproportionate number of medically disadvantaged, low socio-economic citizens. KCI has a long-standing and extensive commitment to both research and clinical services that address the prevention, early detection and treatment of cancer, particularly of African Americans who carry a disproportionate cancer burden. This application requests support for five Programs, ten Cores, Developmental Funds, five Staff Investigators, and related administrative support. KCI's established Programs are Breast Cancer Biology;Developmental Therapeutics;Molecular Biology and Genetics;Population Studies and Disparities Research, and Proteases and Cancer. Our Programs are organized to integrate basic, translational, and clinical research with population research-based cancer control activities. Additionally, CCSG support is requested for ten Cores, in Behavioral and Field Research;Biorepository;Epidemiology Research;Genomics;Microscopy, Imaging and Cytometry Resources;Pharmacology;Proteomics;Systems and Computational Biology;Biostatistics;and Clinical Trials Office. KCI fosters inter-disciplinary interactions and collaborations, utilizes CCSG Developmental Funds to recruit new investigators, encourages translational research Programs, and develops new Shared Resources (Cores) to support KCI members. Research growth continues, as demonstrated by increases in the number of publications and the recruitment of internationally recognized scientists. KCI has 235 members, 170 are Scientific Members and 65 are Clinical Members representing 40 departments and institutes from Wayne State University, Henry Ford Health System, University of Windsor, and Michigan State University. KCI's total annual direct grant funding is $63,296,703 of which $42,441,739 is peer reviewed funding. Of the peer reviewed funding, 6 1 % is from NCI. Over the last grant period, members'published 2,980 papers, 38% and 35% were intra- and inter-programmatic, respectively and 24% were both intra- and inter-programmatic.

Public Health Relevance

Cancer is the second leading cause of mortality in the United States and disproportionately affects minorities. It is through the clinical, basic, population and translational research conducted at KCI that we can make strides towards reducing mortality and morbidity associated with cancer, with a continued commitment to address the disproportionate cancer burden among minorities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA022453-31S1
Application #
8709335
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ptak, Krzysztof
Project Start
1997-08-08
Project End
2015-11-30
Budget Start
2013-09-30
Budget End
2013-11-30
Support Year
31
Fiscal Year
2013
Total Cost
$12,500
Indirect Cost
$4,276
Name
Wayne State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Bock, Cathryn H; Jay, Allison M; Dyson, Gregory et al. (2018) The effect of genetic variants on the relationship between statins and breast cancer in postmenopausal women in the Women's Health Initiative observational study. Breast Cancer Res Treat 167:741-749
Hastert, T A; de Oliveira Otto, M C; LĂȘ-Scherban, F et al. (2018) Association of plasma phospholipid polyunsaturated and trans fatty acids with body mass index: results from the Multi-Ethnic Study of Atherosclerosis. Int J Obes (Lond) 42:433-440
Park, Hyo K; Schildkraut, Joellen M; Alberg, Anthony J et al. (2018) Benign gynecologic conditions are associated with ovarian cancer risk in African-American women: a case-control study. Cancer Causes Control 29:1081-1091
Heyza, Joshua; Lei, Wen; Watza, Donovan et al. (2018) Identification and characterization of synthetic viability with ERCC1 deficiency in response to interstrand crosslinks in lung cancer. Clin Cancer Res :
Mittal, Sandeep; Klinger, Neil V; Michelhaugh, Sharon K et al. (2018) Alternating electric tumor treating fields for treatment of glioblastoma: rationale, preclinical, and clinical studies. J Neurosurg 128:414-421
Su, Yongwei; Li, Xinyu; Ma, Jun et al. (2018) Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo. Biochem Pharmacol 148:13-26
Bonomi, Robin; Popov, Vadim; Laws, Maxwell T et al. (2018) Molecular Imaging of Sirtuin1 Expression-Activity in Rat Brain Using Positron-Emission Tomography-Magnetic-Resonance Imaging with [18F]-2-Fluorobenzoylaminohexanoicanilide. J Med Chem 61:7116-7130
Paximadis, Peter; Beebe-Dimmer, Jennifer L; George, Julie et al. (2018) Comparing Treatment Strategies for Stage I Small-cell lung Cancer. Clin Lung Cancer 19:e559-e565
Modi, Dipenkumar; Al-Kadhimi, Zaid; Chen, Wei et al. (2018) A phase II study of tacrolimus and thymoglobulin as graft-versus-host-disease prophylaxis in related donor allogeneic hematopoietic cell transplantation. Am J Hematol 93:E96-E98
Patki, Mugdha; McFall, Thomas; Rosati, Rayna et al. (2018) Chronic p27Kip1 Induction by Dexamethasone Causes Senescence Phenotype and Permanent Cell Cycle Blockade in Lung Adenocarcinoma Cells Over-expressing Glucocorticoid Receptor. Sci Rep 8:16006

Showing the most recent 10 out of 826 publications